{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0"},{"groupId":"OG001","value":"16.8"},{"groupId":"OG002","value":"6.4"}]}],"title":"CIN grade 4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2"},{"groupId":"OG001","value":"8.0"},{"groupId":"OG002","value":"2.1"}]}],"title":"FN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0"},{"groupId":"OG001","value":"7.1"},{"groupId":"OG002","value":"2.7"}]}],"title":"CIN/FN-related hospitalization"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7"},{"groupId":"OG001","value":"8.8"},{"groupId":"OG002","value":"7.7"}]}],"title":"CIN/FN-related chemotherapy disturbance"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7"},{"groupId":"OG001","value":"26.0"},{"groupId":"OG002","value":"13.0"}]}],"title":"Composite^"}],"denoms":[{"counts":[{"groupId":"OG000","value":"251"},{"groupId":"OG001","value":"817"},{"groupId":"OG002","value":"376"}],"units":"Participants"}],"description":"Objective 5: To describe the distribution of chemotherapy dose delays and reductions, surgery delays and cancellations, radiotherapy delays, dose reductions, and cancellations, and mortality (GCSF-related; FN-related; cancer-related; not related to GCSF, FN, or cancer; all-cause); and estimate the time-to-event for such events over the course of EP2006 treatment.\n\nTable presents incidences of different outcomes and composite outcome by prophylaxis decision (relative to guidelines). \\^Composite endpoint includes any of CIN grade 4, FN, CIN/FN-related hospitalization and CIN/FN-related chemotherapy disturbance.\n\nCIN: Chemotherapy-Induced Neutropenia; FN: Febrile Neutropenia; ANC: Absolute Neutrophil count; GIS: GCSF Initiation Score; Prophylaxis decision mentioned below are relative to EORTC guidelines (2010).","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN, undertreated relative to guidelines","id":"OG000","title":"EP2006: Undertreated"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN, correctly treated relative to guidelines","id":"OG001","title":"EP2006: Correctly Treated"},{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN, overtreated relative to guidelines.","id":"OG002","title":"EP2006: Overtreated"}],"paramType":"NUMBER","populationDescription":"Evaluable sample by prophylaxis decision (relative to guidelines)","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Incidence of CIN/FN-related Hospitalization Outcomes by EP2006 Practice Patterns (Relative to Guidelines): Patient Level","type":"PRIMARY","unitOfMeasure":"percentage of participants"}